Reports Q3 revenue $249.3M, consensus $235.8M. “Tandem delivered a strong third quarter performance marked by record quarterly sales, significant gross margin improvement, and meaningful progress on our key strategic initiatives,” said John Sheridan, president and chief executive officer. “We are beginning to see the positive impact of our business transformation, which strengthens our ability to achieve Tandem’s near- and longer-term goals, while continuing our commitment to improve the lives of people with diabetes.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- TNDM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Tandem Diabetes Care’s New Study: A Game Changer for Type 1 Diabetes Management?
- Tandem Diabetes resumed with a Hold at Stifel
- Tandem Diabetes price target raised to $16 from $14 at Truist
- Tandem Diabetes price target raised to $15 from $11 at Citi